Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Monopar Therapeutics Inc.

Headquarters: Wilmette, IL, United States of America
Year Founded: 2014
Status: Public
Industry Sector: HealthTechnology
CEO: Chandler Drew Robinson, MD, MBA
Number Of Employees: 16
Enterprise Value: $23,172,242
PE Ratio: -8.39
Exchange/Ticker 1: NASDAQ:MNPR
Exchange/Ticker 2: N/A
Latest Market Cap: $211,434,496

BioCentury | Oct 29, 2024
Deals

Novartis adds another degrader, this time from Monte Rosa

Deals report: AbbVie acquires Aliada, Roche returns tau mAb to UCB, Monopar licenses AZ’s Wilson disease program, and more
BioCentury | Oct 29, 2021
Emerging Company Profile

Walden: targeting podocytes as linchpin for kidney function

Backed by Arch and UCB, Walden to enter the clinic next year with a mAb and small molecule targeting podocytes for kidney diseases
BioCentury | Nov 2, 2017
Company News

Monopar gets rights to Onxeo's Validive

Items per page:
1 - 6 of 6